Biotech | January 07, 2022
Lilly and Entos collaborate for therapies in multiple neurologic indications
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The Home Healthcare market is expected to be US $ 14.2 by 2025
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
Subscribe To Our Newsletter & Stay Updated
